We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"Vivek Subbiah, MD (@VivekSubbiah). 44 likes. Delighted to share the final analysis of ARROW trail with pralsetinib in RETaltered thyroid cancers ..."
"Adjuvant treatment with the selective RET inhibitor selpercatinib significantly reduced the risk of disease recurrence, progression, ..."
"The study found that treatment with Retevmo (selpercatinib) reduced the risk of recurrence or death by 83% compared with placebo, highlighting the ..."
"Eli Lilly (LLY) and Company announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in ..."
"Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.